Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check28 days agoChange DetectedThe page has removed a citation for an erratum related to the Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for melanoma, which may affect the accuracy of the information presented.SummaryDifference0.3%
- Check42 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on advanced melanoma, while adding new identifiers and collaborators.SummaryDifference28%
Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.